EntryPoint Capital’s Cymabay Therapeutics CBAY Stock Holding History

EntryPoint Capital’s Portfolio CBAY Stock Details CBAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-6,338	Closed	-$150K	–	1835
2023 Q4	$150K	Buy	+6,338	New	+$113K	0.14%	193

Other funds holding CBAY

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

EntryPoint Capital's CBAY Position: Q1 2024 in Review

EntryPoint Capital sold out of Cymabay Therapeutics (CBAY) in Q1 2024, closing a stake of 6,338 shares — an estimated $150K sold.

EntryPoint Capital first reported a position in CBAY in Q4 2023 and held it in 1 quarter. The position peaked at $150K in Q4 2023. 1 fund tracked by Wall St. Rank holds CBAY as of Q1 2024.

EntryPoint Capital reported no remaining Cymabay Therapeutics position as of Q1 2024 after selling out during the quarter.
EntryPoint Capital sold 6,338 Cymabay Therapeutics shares in Q1 2024, an estimated $150K.
EntryPoint Capital first reported a position in Cymabay Therapeutics in Q4 2023 and held it in 1 quarter.
EntryPoint Capital's Cymabay Therapeutics position peaked at $150K in Q4 2023.
1 fund tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2024.

Based on EntryPoint Capital's 13F filing for Q1 2024, filed 14 May 2024.